Rejuvenate Bio develops gene therapies for age-related disease, with lead programs aimed at both human and animal health. Its platform uses adeno-associated virus delivery to modulate genes such as FGF21 and sTGFβR2, and the company has reported work on canine mitral valve disease and canine osteoarthritis alongside human indications including heart failure, obesity, type 2 diabetes, and kidney disease. Rejuvenate Bio raised more than $10 million in a Series A round, which was reported in 2020, though the lead investors were not stated in the sources provided. Sources also place the company in San Diego, California, and note an animal-health commercialization strategy through partnerships with companies such as Phibro Animal Health and another unnamed leading animal health company.